152 related articles for article (PubMed ID: 30129511)
1. Gender and Ethnicity of Enrolled Participants in U.S. Food and Drug Administration (FDA) Clinical Trials for Approved Ophthalmological New Molecular Entities.
Birnbaum FA
J Natl Med Assoc; 2018 Oct; 110(5):473-479. PubMed ID: 30129511
[TBL] [Abstract][Full Text] [Related]
2. Participation of women in clinical trials for new drugs approved by the food and drug administration in 2000-2002.
Yang Y; Carlin AS; Faustino PJ; Motta MI; Hamad ML; He R; Watanuki Y; Pinnow EE; Khan MA
J Womens Health (Larchmt); 2009 Mar; 18(3):303-10. PubMed ID: 19243271
[TBL] [Abstract][Full Text] [Related]
3. Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017.
Ramamoorthy A; Knepper TC; Merenda C; Mendoza M; McLeod HL; Bull J; Zhang L; Pacanowski M
Clin Pharmacol Ther; 2018 Nov; 104(5):940-948. PubMed ID: 30218447
[TBL] [Abstract][Full Text] [Related]
4. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals.
Downing NS; Shah ND; Neiman JH; Aminawung JA; Krumholz HM; Ross JS
Trials; 2016 Apr; 17():199. PubMed ID: 27079511
[TBL] [Abstract][Full Text] [Related]
5. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of worldwide clinical trials by gender: An FDA perspective.
Ayuso E; Geller RJ; Wang J; Whyte J; Jenkins M
Contemp Clin Trials; 2019 May; 80():16-21. PubMed ID: 30890465
[TBL] [Abstract][Full Text] [Related]
7. Representation of Women and Minorities in Clinical Trials for New Molecular Entities and Original Therapeutic Biologics Approved by FDA CDER from 2013 to 2015.
Chen A; Wright H; Itana H; Elahi M; Igun A; Soon G; Pariser AR; Fadiran EO
J Womens Health (Larchmt); 2018 Apr; 27(4):418-429. PubMed ID: 29048983
[TBL] [Abstract][Full Text] [Related]
8. Timing of pivotal clinical trial results reporting for newly approved medications varied by reporting source.
Withycombe B; Ovenell M; Meeker A; Ahmed SM; Hartung DM
J Clin Epidemiol; 2016 Sep; 77():78-83. PubMed ID: 27108488
[TBL] [Abstract][Full Text] [Related]
9. Racial/Ethnic composition of study participants in FDA-approved oncology new molecular entities, 2006-2008.
Merenda C
J Natl Med Assoc; 2012; 104(9-10):430-5. PubMed ID: 23342816
[TBL] [Abstract][Full Text] [Related]
10. Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients?
Fox-Rawlings SR; Gottschalk LB; Doamekpor LA; Zuckerman DM
Milbank Q; 2018 Sep; 96(3):499-529. PubMed ID: 30203600
[TBL] [Abstract][Full Text] [Related]
11. Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs.
Khan MS; Shahid I; Siddiqi TJ; Khan SU; Warraich HJ; Greene SJ; Butler J; Michos ED
J Am Heart Assoc; 2020 Jun; 9(11):e015594. PubMed ID: 32427023
[TBL] [Abstract][Full Text] [Related]
12. Availability of comparative efficacy data at the time of drug approval in the United States.
Goldberg NH; Schneeweiss S; Kowal MK; Gagne JJ
JAMA; 2011 May; 305(17):1786-9. PubMed ID: 21540422
[TBL] [Abstract][Full Text] [Related]
13. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities.
Stewart JH; Bertoni AG; Staten JL; Levine EA; Gross CP
Ann Surg Oncol; 2007 Dec; 14(12):3328-34. PubMed ID: 17682824
[TBL] [Abstract][Full Text] [Related]
14. Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999.
Evelyn B; Toigo T; Banks D; Pohl D; Gray K; Robins B; Ernat J
J Natl Med Assoc; 2001 Dec; 93(12 Suppl):18S-24S. PubMed ID: 11798060
[TBL] [Abstract][Full Text] [Related]
15. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
[TBL] [Abstract][Full Text] [Related]
16. Update on regulatory review intervals for ophthalmic new drug applications at the United States Food and Drug Administration.
Novack GD
Am J Ophthalmol; 2000 Nov; 130(5):664-5. PubMed ID: 11078847
[TBL] [Abstract][Full Text] [Related]
17. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation.
Rising K; Bacchetti P; Bero L
PLoS Med; 2008 Nov; 5(11):e217; discussion e217. PubMed ID: 19067477
[TBL] [Abstract][Full Text] [Related]
18. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
19. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.
Poon R; Khanijow K; Umarjee S; Fadiran E; Yu M; Zhang L; Parekh A
J Womens Health (Larchmt); 2013 Jul; 22(7):604-16. PubMed ID: 23768021
[TBL] [Abstract][Full Text] [Related]
20. Increasing participation of women in early phase clinical trials approved by the FDA.
Pinnow E; Sharma P; Parekh A; Gevorkian N; Uhl K
Womens Health Issues; 2009; 19(2):89-93. PubMed ID: 19272558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
